Zai Lab Limited (HKG:9688)
24.96
+0.64 (2.63%)
Sep 29, 2025, 2:46 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $109.98M USD in the quarter ending June 30, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $427.80M, up 32.56% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$427.80M
Revenue Growth
+32.56%
P/S Ratio
8.15
Revenue / Employee
$228.89K
Employees
1,869
Market Cap
27.37B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
Innovent Biologics | 12.52B |
WuXi Biologics | 21.98B |
Sino Biopharmaceutical | 33.49B |
Akeso | 2.75B |
Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
Zai Lab News
- 17 days ago - Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
- 17 days ago - Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
- 18 days ago - China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order - Investor's Business Daily
- 19 days ago - Zai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 22 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB - GlobeNewsWire
- 25 days ago - Amgen dips after trial update for Zai Lab partnered gastric cancer therapy - Seeking Alpha
- 27 days ago - Zai Lab Ltd (ZLAB) Secures Approval for TIVDAK in Hong Kong | ZLAB stock news - GuruFocus
- 27 days ago - Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical ... - GuruFocus